Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:ASNDNASDAQ:ATHANYSE:JNJNYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$193.80-0.7%$196.46$153.58▼$218.66$343.54B0.556.06 million shs2.63 million shsASNDAscendis Pharma A/S$167.61-1.7%$154.57$111.09▼$173.25$10.18B0.54489,099 shs387,610 shsATHAAthira Pharma$0.29+1.2%$0.31$0.22▼$3.67$11.13M3.051.48 million shs45,135 shsJNJJohnson & Johnson$154.82-1.0%$159.24$140.68▼$169.99$372.99B0.497.90 million shs2.69 million shsJNJJohnson & Johnson$154.82-1.0%$159.24$140.68▼$169.99$372.99B0.497.90 million shs2.69 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.83%+10.08%-7.00%+11.17%+19.95%ASNDAscendis Pharma A/S+2.32%+7.78%+9.35%+33.89%+23.11%ATHAAthira Pharma-6.13%-2.15%+0.57%-47.27%-85.71%JNJJohnson & Johnson+0.27%+0.63%-5.77%+2.32%+8.10%JNJJohnson & Johnson+0.27%+0.63%-5.77%+2.32%+8.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.6176 of 5 stars2.44.04.23.92.72.51.3ASNDAscendis Pharma A/S2.3116 of 5 stars3.52.00.00.02.81.70.6ATHAAthira Pharma3.2147 of 5 stars3.05.00.00.03.31.71.3JNJJohnson & Johnson4.6437 of 5 stars3.33.04.23.92.72.50.6JNJJohnson & Johnson4.6437 of 5 stars3.33.04.23.92.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.89Moderate Buy$211.419.09% UpsideASNDAscendis Pharma A/S 2.93Moderate Buy$204.6722.11% UpsideATHAAthira Pharma 2.00Hold$13.834,753.80% UpsideJNJJohnson & Johnson 2.63Moderate Buy$171.8210.98% UpsideJNJJohnson & Johnson 2.63Moderate Buy$171.8210.98% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, JNJ, ATHA, ASND, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.004/28/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$210.004/17/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$214.00 ➝ $214.004/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.09$14.32 per share13.53$1.90 per share102.00ASNDAscendis Pharma A/S$363.64M28.10N/AN/A($1.88) per share-89.15ATHAAthira PharmaN/AN/AN/AN/A$3.42 per shareN/AJNJJohnson & Johnson$89.33B4.17$12.72 per share12.17$29.69 per share5.21JNJJohnson & Johnson$89.33B4.17$12.72 per share12.17$29.69 per share5.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3580.9213.861.627.59%296.28%12.65%N/AASNDAscendis Pharma A/S-$409.12M-$7.10N/A698.36N/A-104.54%N/A-39.23%5/1/2025 (Estimated)ATHAAthira Pharma-$117.67M-$2.53N/AN/AN/AN/A-115.62%-88.94%5/13/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9923.3113.992.5618.20%34.24%13.63%7/16/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9923.3113.992.5618.20%34.24%13.63%7/16/2025 (Estimated)Latest ABBV, JNJ, ATHA, ASND, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025ATHAAthira Pharma-$0.20N/AN/AN/AN/AN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56N/AN/AN/A$98.56 millionN/A4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion2/27/2025Q4 2024ATHAAthira Pharma-$0.45-$0.39+$0.06-$0.39N/AN/A2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.38%+6.04%279.15%53 YearsASNDAscendis Pharma A/SN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.36%+5.43%57.84%64 YearsJNJJohnson & Johnson$5.203.36%+5.43%57.84%64 YearsLatest ABBV, JNJ, ATHA, ASND, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/20254/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/20252/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55ASNDAscendis Pharma A/SN/A1.170.84ATHAAthira PharmaN/A2.952.95JNJJohnson & Johnson0.431.110.86JNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ASNDAscendis Pharma A/SN/AATHAAthira Pharma57.12%JNJJohnson & Johnson69.55%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ASNDAscendis Pharma A/S40.00%ATHAAthira Pharma19.80%JNJJohnson & Johnson0.16%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableATHAAthira Pharma4039.04 million31.01 millionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableABBV, JNJ, ATHA, ASND, and JNJ HeadlinesRecent News About These CompaniesJohnson & Johnson (NYSE:JNJ) Stake Raised by RBO & Co. LLCMay 1 at 8:19 AM | marketbeat.comParvin Asset Management LLC Buys Shares of 4,670 Johnson & Johnson (NYSE:JNJ)May 1 at 8:09 AM | marketbeat.comGuardian Capital LP Grows Position in Johnson & Johnson (NYSE:JNJ)May 1 at 8:07 AM | marketbeat.comBison Wealth LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)May 1 at 7:56 AM | marketbeat.comBecker Capital Management Inc. Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)May 1 at 7:35 AM | marketbeat.comConnors Investor Services Inc. Has $524,000 Position in Johnson & Johnson (NYSE:JNJ)May 1 at 7:33 AM | marketbeat.comComerica Bank Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)May 1 at 7:23 AM | marketbeat.comKapitalo Investimentos Ltda Purchases Shares of 2,429 Johnson & Johnson (NYSE:JNJ)May 1 at 6:59 AM | marketbeat.comVoleon Capital Management LP Invests $16.41 Million in Johnson & Johnson (NYSE:JNJ)May 1 at 6:45 AM | marketbeat.comUS FDA approves Johnson & Johnson’s drug for immune-mediated disorderMay 1 at 5:05 AM | msn.comJnJ Imaavy gets USFDA okay for generalized myasthenia gravisMay 1 at 5:05 AM | medicaldialogues.inIs Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?April 30 at 7:03 PM | msn.comJohnson & Johnson Shareholders Approve 2025 Director NomineesApril 30 at 5:36 PM | tipranks.comJohnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?April 30 at 4:36 PM | insidermonkey.comJohnson & Johnson (NYSE:JNJ) Trading Up 0.7% - What's Next?April 30 at 2:26 PM | marketbeat.comFDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for FamiliesApril 30 at 1:42 PM | globenewswire.comFDA Greenlights Johnson & Johnson's gMG Treatment Imaavy (JNJ)April 30 at 10:25 AM | gurufocus.comJohnson & Johnson (JNJ) Gains FDA Approval for Imaavy in Treating gMG | JNJ Stock NewsApril 30 at 9:33 AM | gurufocus.comUS FDA approves J&J's immune disorder drugApril 30 at 8:41 AM | reuters.comJohnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)April 30 at 8:29 AM | prnewswire.comSchonfeld Strategic Advisors LLC Sells 265,824 Shares of Johnson & Johnson (NYSE:JNJ)April 30 at 8:19 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s LeadBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentIf You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBy Thomas Hughes | April 25, 2025View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? ABBV, JNJ, ATHA, ASND, and JNJ Company DescriptionsAbbVie NYSE:ABBV$193.80 -1.30 (-0.67%) As of 01:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Ascendis Pharma A/S NASDAQ:ASND$167.61 -2.83 (-1.66%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Athira Pharma NASDAQ:ATHA$0.28 +0.00 (+1.21%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Johnson & Johnson NYSE:JNJ$154.82 -1.49 (-0.95%) As of 01:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Johnson & Johnson NYSE:JNJ$154.82 -1.49 (-0.95%) As of 01:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
